EAM
KPTI icon

EverPoint Asset Management’s Karyopharm Therapeutics KPTI Stock Holding History

EverPoint Asset Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-4,323
Closed -$2.27M – 503
2014
Q3 		$2.27M Sell
4,323
-1,010
-19% -$570K 0.05% 344
2014
Q2 		$3.72M Buy
+5,333
New +$2.48M 0.08% 314

Other funds holding KPTI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
FCMI
Foresite Capital Management I Larkspur, California $21.4M AUM 80.48% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EverPoint Asset Management's KPTI Position: Q4 2014 in Review

EverPoint Asset Management sold out of Karyopharm Therapeutics (KPTI) in Q4 2014, closing a stake of 4,323 shares — an estimated $2.27M sold.

EverPoint Asset Management first reported a position in KPTI in Q2 2014 and held it in 2 quarters. The position peaked at $3.72M in Q2 2014. 81 funds tracked by Wall St. Rank hold KPTI as of Q4 2014.

  • EverPoint Asset Management reported no remaining Karyopharm Therapeutics position as of Q4 2014 after selling out during the quarter.
  • EverPoint Asset Management sold 4,323 Karyopharm Therapeutics shares in Q4 2014, an estimated $2.27M.
  • EverPoint Asset Management first reported a position in Karyopharm Therapeutics in Q2 2014 and held it in 2 quarters.
  • EverPoint Asset Management's Karyopharm Therapeutics position peaked at $3.72M in Q2 2014.
  • 81 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2014.

Based on EverPoint Asset Management's 13F filing for Q4 2014, filed 17 Feb 2015.